Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8471-8489

  Mooring, Suazette Reid ^a   Jin, Hui ^a   Devi, Narra S ^b   Jabbar, Adnan A ^b   Kaluz, Stefan ^b,c   Liu, Yuan ^c   Van Meir, Erwin G ^b,c   Wang, Binghe ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 BROMOPHENYL)(2,2 DIMETHYL 2H CHROME 6 YL METHYL)AMINE; (2,2 DIMETHYL 2H CHROMEN 6 YL METHYL )(2,4 DIMETHYLPHENYL)AMINE; (2,2 DIMETHYL 2H CHROMEN 6 YL METHYL )(2,4 DIMETHYLPHENYL)METHYLAMINE; (2,2 DIMETHYL 2H CHROMEN 6 YL METHYL)(2 FLUOROPHENYL)AMINE; (2,2 DIMETHYL 2H CHROMEN 6 YL METHYL)METHYLPYRIDIN 2 YL AMINE; (2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL)METHYLPYRIDIN 2 YL AMINE; (3,4 DIMETHOXYPHENYL)(2,2 DIMETHYL 2H CHROMEN 6 YL METHYL)METHYLAMINE; (3,4 DIMETHOXYPHENYL)(2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL)AMINE; 2 ETHYL 2 METHYLBENZOPYRAN DERIVATIVE; 2,5 DICHLORO N [(2,2 DIMETHYL 2H CHROMEN 6 YL)METHYL] N PHENYLBENZENESULFONAMIDE; 4 (3 METHYLPENT 1 YN 3 YLOXY)BENZALDEHYDE; 4 [(2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL)AMINO]BENZOIC ACID; 4,4 BROMO N [(2,2 DIMETHYL 2H CHROMEN 6 YL)METHYL] N PHENYL 2 (TRIFLUOROMETHOXY)BENZENESULFONAMIDE; AMIDE; BENZOFURAN DERIVATIVE; BENZOPYRAN DERIVATIVE; HYPOXIA INDUCIBLE FACTOR; N (2,2 DIMETHYL 2H CHROMEN 6 YL METHYL) N ISOPROPYL 3,4 DIMETHOXYBENZENESULFONAMIDE; N (2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL) 3,4 DIMETHOXY N (3 METHYLBUTYL)BENZENESULFONAMIDE; N (2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL) 3,4 DIMETHOXY N PROP 2 YNYLBENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMEN 6 YL)METHYL] 4 METHOXY N PHENYLBENZENESULFONAMIDE; N ALLYL N (2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL) 3,4 DIMETHOXYBENZENESULFONAMIDE; N BUTYL N (2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL) 3,4 DIMETHOXYBENZENESULFONAMIDE; N CYCLOPENTYL N (2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL) 3,4 DIMETHOXYBENZENESULFONAMIDE; N CYCLOPROPYL N (2,2 DIMETHYL 2H CHROMEN 6 YLMETHYL) 3,4 DIMETHOXYBENZENESULFONAMIDE; PYRAN DERIVATIVE; PYRANOPYRIDINE; PYRIDINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOLOGY; CHEMISTRY; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BENZOFURANS; BENZOPYRANS; CELL HYPOXIA; CELL LINE, TUMOR; CREB-BINDING PROTEIN; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; P300-CBP TRANSCRIPTION FACTORS; PYRIDINES; QUINOLINES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84055221822     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201018g     Document Type: Article

References (44)

1. Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8 (9), 705-713.
2. Pouyssegur, J.; Dayan, F.; Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441 (7092), 437-443.
3. Kaur, B.; Tan, C.; Brat, D. J.; Post, D. E.; Van Meir, E. G. Genetic and hypoxic regulation of angiogenesis in gliomas. J. Neuro-Oncol. 2004, 70 (2), 229-243.
4. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58 (7), 1408-1416.
5. Harris, A. L. Hypoxia: a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2 (1), 38-47.
6. Greijer, A. E.; van der Groep, P.; Kemming, D.; Shvarts, A.; Semenza, G. L.; Meijer, G. A.; van de Wiel, M. A.; Belien, J. A.; van Diest, P. J.; van der Wall, E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J. Pathol. 2005, 206 (3), 291-304.
7. Semenza, G. L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29 (5), 625-634.
8. Kaelin, W. G. Jr.; Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30 (4), 393-402.
9. Kaluz, S.; Kaluzova, M.; Stanbridge, E. J. Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity. J. Cell. Biochem. 2008, 104 (2), 536-544.
10. Ohh, M.; Park, C. W.; Ivan, M.; Hoffman, M. A.; Kim, T. Y.; Huang, L. E.; Pavletich, N.; Chau, V.; Kaelin, W. G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2000, 2 (7), 423-427.
11. Bruick, R. K.; McKnight, S. L. A conserved family of prolyl-4- hydroxylases that modify HIF. Science 2001, 294 (5545), 1337-1340.
12. Epstein, A. C. R.; Gleadle, J. M.; McNeill, L. A.; Hewitson, K. S.; O'Rourke, J.; Mole, D. R.; Mukherji, M.; Metzen, E.; Wilson, M. I.; Dhanda, A.; Tian, Y. M.; Masson, N.; Hamilton, D. L.; Jaakkola, P.; Barstead, R.; Hodgkin, J.; Maxwell, P. H.; Pugh, C. W.; Schofield, C. J.; Ratcliffe, P. J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107 (1), 43-54.
13. Maxwell, P. H. The HIF pathway in cancer. Semin. Cell Dev. Biol. 2005, 16 (4-5), 523-530.
14. Schofield, C. J.; Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5 (5), 343-354.
15. Kaur, B.; Khwaja, F. W.; Severson, E. A.; Matheny, S. L.; Brat, D. J.; Van Meir, E. G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncol. 2005, 7 (2), 134-153.
16. Tsuzuki, Y.; Fukumura, D.; Oosthuyse, B.; Koike, C.; Carmeliet, P.; Jain, R. K. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1 alpha → hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 2000, 60 (22), 6248-6252.
17. Bos, R.; van der Groep, P.; Greijer, A. E.; Shvarts, A.; Meijer, S.; Pinedo, H. M.; Semenza, G. L.; van Diest, P. J.; van der Wall, E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97 (6), 1573-1581.
18. Talks, K. L.; Turley, H.; Gatter, K. C.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 2000, 157 (2), 411-421.
19. Zhong, H.; De Marzo, A. M.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G. L.; Simons, J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59 (22), 5830-5835.
20. Aebersold, D. M.; Burri, P.; Beer, K. T.; Laissue, J.; Djonov, V.; Greiner, R. H.; Semenza, G. L. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61 (7), 2911-2916.
21. Birner, P.; Gatterbauer, B.; Oberhuber, G.; Schindl, M.; Rossler, K.; Prodinger, A.; Budka, H.; Hainfellner, J. A. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001, 92 (1), 165-171.
22. Birner, P.; Schindl, M.; Obermair, A.; Plank, C.; Breitenecker, G.; Oberhuber, G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60 (17), 4693-4696.
23. Koukourakis, M. I.; Bentzen, S. M.; Giatromanolaki, A.; Wilson, G. D.; Daley, F. M.; Saunders, M. I.; Dische, S.; Sivridis, E.; Harris, A. L. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 2006, 24 (5), 727-735.
24. Post, D. E.; Devi, N. S.; Li, Z.; Brat, D. J.; Kaur, B.; Nicholson, A.; Olson, J. J.; Zhang, Z.; Van Meir, E. G. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin. Cancer Res. 2004, 10 (24), 8603-8612.
25. Post, D. E.; Sandberg, E. M.; Kyle, M. M.; Devi, N. S.; Brat, D. J.; Xu, Z.; Tighiouart, M.; Van Meir, E. G. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 2007, 67 (14), 6872-6881.
26. Post, D. E.; Van Meir, E. G. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther. 2001, 8 (23), 1801-1807.
27. Post, D. E.; Van Meir, E. G. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003, 22 (14), 2065-2072.
28. Melillo, G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 2006, 4 (9), 601-605.
29. Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discovery Today 2007, 12 (19-20), 853-859.
30. Belozerov, V. E.; Van Meir, E. G. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005, 16 (9), 901-909.
31. Fujii, M.; Egawa, K.; Hirai, Y.; Kondo, M.; Akita, H.; Nose, K.; Toriizuka, K.; Ida, Y. First synthesis of racemic methylophiopogona-none B and its inhibitory activity of hypoxia-inducible factor-1 alpha. Heterocycles 2009, 78 (1), 207-212.
32. Nicolaou, K. C.; Pfefferkorn, J. A.; Mitchell, H. J.; Roecker, A. J.; Barluenga, S.; Cao, G. Q.; Affleck, R. L.; Lillig, J. E. Natural productlike combinatorial libraries based on privileged structures. 2. Construction of a 10 000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J. Am. Chem. Soc. 2000, 122 (41), 9954-9967.
33. Tan, C.; de Noronha, R. G.; Roecker, A. J.; Pyrzynska, B.; Khwaja, F.; Zhang, Z.; Zhang, H.; Teng, Q.; Nicholson, A. C.; Giannakakou, P.; Zhou, W.; Olson, J. J.; Pereira, M. M.; Nicolaou, K. C.; Van Meir, E. G. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005, 65 (2), 605-612.
34. Narita, T.; Yin, S.; Gelin, C. F.; Moreno, C. S.; Yepes, M.; Nicolaou, K. C.; Van Meir, E. G. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin. Cancer Res. 2009, 15 (19), 6128-6136.
35. Tan, C.; de Noronha, R. G.; Devi, N. S.; Jabbar, A. A.; Kaluz, S.; Liu, Y.; Mooring, S. R.; Nicolaou, K. C.; Wang, B.; Van Meir, E. G. Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg. Med. Chem. Lett. 2011, 21 (18), 5528-5532.
36. Van Meir, E. G.; et al. A novel class of anti-tumor agents that modulate the p300/CBP HIF-1 interaction and inhibit hypoxia signaling. Manuscript in preparation.
37. Grossniklaus, H. E.; et al. Efficacy of the novel small molecule HIF pathway inhibitor KCN1 in the control of micrometastases in experimental ocular melanoma. Manuscript in preparation.
38. Liebmann, J.; Cook, J. A.; Mitchell, J. B. Cremophor EL, solvent for paclitaxel, and toxicity. Lancet 1993, 342 (8884), 1428.
39. Prado, S.; Janin, Y. L.; Saint-Joanis, B.; Brodin, P.; Michel, S.; Koch, M.; Cole, S. T.; Tillequin, F.; Bost, P.-E. Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. Bioorg. Med. Chem. 2007, 15 (5), 2177-2186.
40. Evans, J. M.; Stemp, G. Short efficient syntheses of 2,2-dimethyl-2H- pyranopyridines. Synth. Commun. 1988, 18 (10), 1111-1118.
41. Robert, N.; Hoarau, C.; Celanire, S.; Ribereau, P.; Godard, A.; Queguiner, G.; Marsais, F. Efficient and fast Heck vinylation of 2-bromo-6-methyl pyridines with methylacrylate. Application to the synthesis of 6-methyl cyclopenta[b]pyridinone. Tetrahedron 2005, 61 (19), 4569-4576.
42. Lindstrom, M. J.; Bates, D. M. Nonlinear mixed effects models for repeated measures data. Biometrics 1990, 46 (3), 673-687.
43. Pinheiro J., B. D., DebRoy S., Sarkar D.; R Development Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R Package, version 3; 2009, pp 1-96.
44. Kaluz, S.; Kaluzova, M.; Stanbridge, E. J. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol. Cell. Biol. 2006, 26 (15), 5895-5907.